From this, we have hypothesized that patients who show a higher degree of HER2 trogocytosis prior to trastuzumab administration might show a better response to trastuzumab treatment; trastuzumab targeting of HER2+ tumor cells in these patients could be more effective and result in greater immune cell ADCC. The gene discussed is ERBB2; the disease is neoplasm.